Combination of teriflunomide and interferon as follow-up therapy after fingolimod-associated PML
نویسندگان
چکیده
منابع مشابه
Evaluating the efficacy and side effects fingolimod in 3 -year follow-up of patients in RRMS
Fingolimod is the first DMT drug to treat MS that oral form was available. This study was done with aim to study the effectiveness and long-term side effects of bio similar fingolimod oral forms in 3-year follow-up of patients with RRMS. Methods: This study was a clinical trial (before and after) on 28 patients with RRMS referring to Clinic of Imam Reza Hospital in Kermanshah. Patients r...
متن کاملPML-IRIS during Fingolimod Diagnosed after Natalizumab Discontinuation
Background. Natalizumab treatment is frequently discontinued and replaced by alternative medication in multiple sclerosis (MS) patients having a high risk of progressive multifocal leukoencephalopathy (PML). Case Presentation. We report a PML case that was missed on magnetic resonance imaging (MRI) at the time Natalizumab treatment was discontinued. The patient subsequently developed a PML-immu...
متن کاملEfficacy and Long-Term Follow Up of Combination Therapy with Interferon Alpha and Ribavirin for Chronic Hepatitis C in Korea
Combination therapy with interferon alpha (IFN-alpha) and ribavirin for 24 or 48 weeks according to HCV genotype has improved the overall sustained virological response (SVR) rates to approximately 40%. The aim of this study was to investigate the long-term efficacy of combination therapy with IFN-alpha and ribavirin for chronic hepatitis C in Koreans. One hundred thirty-eight patients with chr...
متن کاملEFFICACY AND SAFETY OF COMBINATION THERAPY OF INTERFERON-ALPHA 2B PLUS RIBAVIRIN FOR CHRONIC HEPATITIS C
Introduction: The aim of this study is to assess the therapeutic efficacy and safety of a particular brand of IFN alpha (PDferon B®) in combination with ribavirin (RlBA) on Iranian patients with chronic hepatitis C (CHC). The addition of RIBA to the standard treatment with interferon (IFN) alpha led to an improvement in sustained virologic response (SVR) from less than 20% with IFN monother...
متن کاملLong-term safety and efficacy of teriflunomide: Nine-year follow-up of the randomized TEMSO study.
OBJECTIVE To report safety and efficacy outcomes from up to 9 years of treatment with teriflunomide in an extension (NCT00803049) of the pivotal phase 3 Teriflunomide Multiple Sclerosis Oral (TEMSO) trial (NCT00134563). METHODS A total of 742 patients entered the extension. Teriflunomide-treated patients continued the original dose; those previously receiving placebo were randomized 1:1 to te...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Neurology - Neuroimmunology Neuroinflammation
سال: 2020
ISSN: 2332-7812
DOI: 10.1212/nxi.0000000000000927